Founded in 2014 by a team of former drug developers from multi-national pharma organizations and leading academics, Antaros is a leading advanced imaging service provider specializing in the development of novel and value-added biomarkers and the delivery of tailored imaging clinical trial solutions for biopharma and biotech sponsors. The company’s expertise spans all imaging modalities with a focus on magnetic resonance imaging (MRI) and positron emission tomography (PET), and leverages AI-enabled algorithms developed in-house to deliver unique insights to its clients.

Antaros has established a robust track record of successful clinical trial execution within the metabolic disease area including obesity, in renal and cardiometabolic disease, and in fibrosis, with emerging presences in neurology, immunology, and oncology. Antaros has run more than 110 clinical trials at more than 600 sites globally — including high-profile collaborations with more than half of the top-20 biopharma sponsors. The company’s unique capabilities and proprietary insights enable these clients to make superior decisions in their clinical development programs, saving time and money and speeding new medicines to market.